{
    "nct_id": "NCT03436485",
    "official_title": "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer",
    "inclusion_criteria": "* Written informed consent (IC) obtained.\n* Male aged â‰¥ 18 years.\n* Histologically confirmed adenocarcinoma of the prostate.\n* Castration resistant prostate cancer with serum testosterone < 50 ng/dl.\n* Metastatic disease.\n* Ongoing androgen deprivation therapy with GnRH analogue or antagonist, or have had bilateral orchiectomy.\n* Received at least one prior line of novel hormonal androgen receptor (AR) targeted therapy (e.g. abiraterone, enzalutamide).\n* ECOG performance status 0-1.\n* Adequate marrow, liver and kidney function.\n* Able to swallow study treatment.\n* Part 1: Treatment with at least 1 line of chemotherapy or ineligibility for chemotherapy. Part 2: Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC.\n\nMain\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of pituitary or adrenal dysfunction.\n* Known brain metastases or active leptomeningeal disease.\n* Active infection or other medical condition that would make corticosteroid contraindicated.\n* Poorly controlled diabetes.\n* Hypotension or uncontrolled hypertension.\n* Clinically significantly abnormal serum potassium or sodium level.\n* Active or unstable cardio/cerebro-vascular disease including thromboembolic events.\n* Prolonged QTcF interval.",
    "miscellaneous_criteria": "Main"
}